JP2020526505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526505A5 JP2020526505A5 JP2019572570A JP2019572570A JP2020526505A5 JP 2020526505 A5 JP2020526505 A5 JP 2020526505A5 JP 2019572570 A JP2019572570 A JP 2019572570A JP 2019572570 A JP2019572570 A JP 2019572570A JP 2020526505 A5 JP2020526505 A5 JP 2020526505A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- substituted
- hydrogen
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000007803 itching Effects 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000005549 barrier dysfunction Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529846P | 2017-07-07 | 2017-07-07 | |
| US62/529,846 | 2017-07-07 | ||
| PCT/US2018/041086 WO2019010414A1 (en) | 2017-07-07 | 2018-07-06 | FATTY ACID DERIVATIVES AND USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526505A JP2020526505A (ja) | 2020-08-31 |
| JP2020526505A5 true JP2020526505A5 (enExample) | 2021-07-26 |
| JP7234151B2 JP7234151B2 (ja) | 2023-03-07 |
Family
ID=63036390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572570A Active JP7234151B2 (ja) | 2017-07-07 | 2018-07-06 | 脂肪酸誘導体およびこれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11555021B2 (enExample) |
| EP (1) | EP3649115B1 (enExample) |
| JP (1) | JP7234151B2 (enExample) |
| KR (1) | KR102725883B1 (enExample) |
| CN (1) | CN110869354A (enExample) |
| AU (1) | AU2018297192B2 (enExample) |
| CA (1) | CA3064132C (enExample) |
| MX (1) | MX391168B (enExample) |
| WO (1) | WO2019010414A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018070164B1 (pt) | 2016-04-01 | 2022-09-27 | Sony Corporation Of America | Corantes diméricos ou poliméricos ultrabrilhantes |
| CN109153860B (zh) | 2016-04-06 | 2021-04-23 | 索尼公司 | 具有间隔连接体基团的超高亮二聚体或聚合物染料 |
| WO2018022925A1 (en) | 2016-07-29 | 2018-02-01 | Sony Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| US12290571B2 (en) | 2017-10-05 | 2025-05-06 | Sony Group Corporation | Programmable dendritic drugs |
| KR20260011205A (ko) | 2017-10-05 | 2026-01-22 | 소니그룹주식회사 | 프로그램가능한 중합체성 약물 |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | 索尼公司 | 可编程的聚合药物 |
| US12076407B2 (en) | 2018-01-12 | 2024-09-03 | Sony Group Corporation | Polymers with rigid spacing groups comprising biologically active compounds |
| EP3737417B1 (en) | 2018-01-12 | 2025-08-27 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| KR102864292B1 (ko) | 2018-03-21 | 2025-09-26 | 소니그룹주식회사 | 링커 군을 갖는 중합체성 텐덤 염료 |
| JP7580689B2 (ja) | 2018-06-27 | 2024-11-12 | ソニーグループ株式会社 | デオキシリボースを含むリンカー基を有するポリマー色素 |
| US12578342B2 (en) | 2018-07-13 | 2026-03-17 | Sony Group Corporation | Polymeric dyes having a backbone comprising organophosphate units |
| EP3861074A2 (en) | 2019-09-26 | 2021-08-11 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
| EP4038081A1 (en) | 2019-09-30 | 2022-08-10 | Sony Group Corporation | Nucleotide probes |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
| CN113121475B (zh) * | 2021-03-30 | 2022-12-02 | 香港科技大学深圳研究院 | 不饱和脂肪酸类化合物及其制备方法和应用 |
| CN113620923B (zh) * | 2021-07-16 | 2023-03-14 | 扬州工业职业技术学院 | 一种低温电解液添加剂的制备方法及应用 |
| CN115073295B (zh) * | 2022-07-21 | 2023-12-26 | 山东大学 | 马齿苋中不饱和脂肪酸及其提取分离方法和应用 |
| WO2024237316A1 (ja) * | 2023-05-16 | 2024-11-21 | 国立大学法人東京大学 | エポキシ化不飽和脂肪酸の皮膚線維化改善作用 |
| EP4613730A1 (en) * | 2024-03-05 | 2025-09-10 | Centre National de la Recherche Scientifique | Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055613A (en) * | 1988-02-18 | 1991-10-08 | G. D. Searle & Co. | Metabolites of pentanedioic acid derivatives |
| ATE168372T1 (de) * | 1993-03-29 | 1998-08-15 | Hsc Res Dev Lp | Hepoxilin analoga verwendbar als entzündungshemmende mittel |
| IL121165A0 (en) * | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| US20020037876A1 (en) * | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| BR0012447A (pt) * | 1999-07-15 | 2002-04-02 | Lilly Co Eli | Análogos de pseudomicina de cadeia lateral de n-acila |
| US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US7335689B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
| DE102004037118A1 (de) | 2004-07-30 | 2006-03-23 | Degussa Ag | Titandioxid enthaltende Dispersion |
| WO2006106438A2 (en) | 2005-01-11 | 2006-10-12 | Evolva Sa | Modulators of ppar activity |
| JP5337479B2 (ja) | 2005-05-04 | 2013-11-06 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 新規化合物 |
| IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
| JP5552121B2 (ja) * | 2008-09-04 | 2014-07-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のインドリジン阻害剤 |
| WO2013157926A1 (en) | 2012-04-19 | 2013-10-24 | Nyken Holding B.V. | Geranyl geranyl acetone analogs and uses thereof |
| JP6160375B2 (ja) | 2013-09-06 | 2017-07-12 | ブラザー工業株式会社 | 画像記録装置 |
-
2018
- 2018-07-06 MX MX2019015730A patent/MX391168B/es unknown
- 2018-07-06 US US16/622,697 patent/US11555021B2/en active Active
- 2018-07-06 EP EP18746415.1A patent/EP3649115B1/en active Active
- 2018-07-06 JP JP2019572570A patent/JP7234151B2/ja active Active
- 2018-07-06 WO PCT/US2018/041086 patent/WO2019010414A1/en not_active Ceased
- 2018-07-06 CA CA3064132A patent/CA3064132C/en active Active
- 2018-07-06 CN CN201880045287.6A patent/CN110869354A/zh active Pending
- 2018-07-06 AU AU2018297192A patent/AU2018297192B2/en active Active
- 2018-07-06 KR KR1020207003568A patent/KR102725883B1/ko active Active
-
2022
- 2022-04-12 US US17/718,965 patent/US12479812B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102725883B1 (ko) | 지방산 유도체 및 이의 용도 | |
| CA1209985A (fr) | Procede de preparation de nouveaux imino acides substitues | |
| US6245811B1 (en) | Fatty acid esters as bioactive compounds | |
| ES2773784T3 (es) | Enantiómeros de 2-hidroxiderivados de ácidos grasos | |
| JP7130818B2 (ja) | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 | |
| JP2010502731A5 (enExample) | ||
| RU2013127162A (ru) | Молекулы аналогов циклоспорина, модифицированные по 1 и 3 аминокислоте | |
| RU2015105893A (ru) | Ингибиторы цистатионин-г-лиазы (cse) | |
| JPH0512329B2 (enExample) | ||
| LU92736I2 (fr) | Ospémifène dans toutes les formes protégées par lebrevet de base | |
| WO2019208392A1 (ja) | 新規プラズマローゲン誘導体 | |
| JP2016193927A (ja) | アミドキシムカルボン酸エステル及びｎ−ヒドロキシグアニジンカルボン酸エステルのプロドラッグの製造のための使用 | |
| WO2019038638A1 (en) | PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA | |
| FR3063645A1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
| EP3126332A1 (en) | Histone acetyltransferase activators and uses thereof | |
| BR112013010508B1 (pt) | Compostos de carboxilato de fenilcetona ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica compreendendo o referido composto e uso do mesmo | |
| BR112014013541B1 (pt) | Processos para a recuperação e preparação de cloridrato de nalmefeno e composto | |
| RU2275906C2 (ru) | Средство для лечения болезни паркинсона, включающее в качестве активного ингредиента соединение, улучшающее астроцитную функцию | |
| US20150119406A1 (en) | Tricyclic pyrone compounds reduce amyloid beta aggregates | |
| US20180065992A1 (en) | Monomeric bimetal hydroxycitric acid compounds and methods of making and using the same | |
| JP7589972B2 (ja) | 小胞型ヌクレオチドトランスポーター阻害剤 | |
| CN101619040A (zh) | 阿扑啡类化合物、其药物组合物及其用途 | |
| EP3075738B1 (en) | Glycyrrhetinic acid derivative and use thereof | |
| JP2008531613A5 (enExample) | ||
| CA2223644A1 (en) | Polycyclic alcaloid-derivatives as nmda-receptor antagonists |